Five-year data from a pivotal Investigational Device Exemption study of Moximed’s MISHA Knee System found that patients had sustained, clinically meaningful pain relief and functional improvement at five years, with proven durability.
Key Findings:
Significant and Sustained Pain Relief: 96% of patients had clinically meaningful improvement in pain at 5-years post-op
Exceptional Improvement in Function: 86% of patients had clinically meaningful improvement in function at 5-years post-op
Proven Durability: 90% of patients were free from conversion to arthroplasty or high tibial osteotomy at 5-years post-op
“Having met multiple patients from this study, it’s amazing to see the profound effect that the MISHA Knee System is having on their lives,” said Christopher Gleason, President and Chief Executive Officer, Moximed. “We are eager to utilize this long-term clinical evidence to expand access for knee OA patients looking for an effective, durable, and joint-sparing treatment option without activity restrictions.”
Five-year data from a pivotal Investigational Device Exemption study of Moximed's MISHA Knee System found that patients had sustained, clinically meaningful pain relief and functional improvement at five years, with proven durability.
Key Findings:
Significant and Sustained Pain Relief: 96% of patients had clinically meaningful...
Five-year data from a pivotal Investigational Device Exemption study of Moximed’s MISHA Knee System found that patients had sustained, clinically meaningful pain relief and functional improvement at five years, with proven durability.
Key Findings:
Significant and Sustained Pain Relief: 96% of patients had clinically meaningful improvement in pain at 5-years post-op
Exceptional Improvement in Function: 86% of patients had clinically meaningful improvement in function at 5-years post-op
Proven Durability: 90% of patients were free from conversion to arthroplasty or high tibial osteotomy at 5-years post-op
“Having met multiple patients from this study, it’s amazing to see the profound effect that the MISHA Knee System is having on their lives,” said Christopher Gleason, President and Chief Executive Officer, Moximed. “We are eager to utilize this long-term clinical evidence to expand access for knee OA patients looking for an effective, durable, and joint-sparing treatment option without activity restrictions.”
Copy to clipboard 
